16 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
24 Aug 23
Regulation FD Disclosure
7:00am
. Cognition Therapeutics – Our Company
6 Within the amyloid hypothesis, oligomers are a pathogenic form produced early in disease Innovation lies
424B4
CGTX
Cognition Therapeutics Inc
14 Nov 22
Prospectus supplement with pricing info
6:02am
impact the timing of the commercial launch of the product.
The Food and Drug Administration Safety and Innovation Act established a category of drugs
DRS
CGTX
Cognition Therapeutics Inc
20 Oct 22
Draft registration statement
12:00am
of the commercial launch of the product.
The Food and Drug Administration Safety and Innovation Act established a category of drugs referred to as “breakthrough
10-K
q4w1ffr2hidqwpbry
30 Mar 22
Annual report
7:40am
10-Q
xibsm
17 Nov 21
Quarterly report
5:15pm
424B4
tdzyv0bvwcm
12 Oct 21
Prospectus supplement with pricing info
4:11pm
S-1
EX-10.2
udo chy1euhwhzdco0
19 Jul 21
IPO registration
7:02am
S-1
0g1kgkypttwos41
19 Jul 21
IPO registration
7:02am
DRS/A
81ds7rjcbav4
23 Jun 21
Draft registration statement (amended)
12:00am
DRS
EX-10.2
3ojeh92crnd q846dlr
7 May 21
Draft registration statement
12:00am
DRS
wk96i
7 May 21
Draft registration statement
12:00am
- Prev
- 1
- Next